James Gordon CFA
Stock Analyst at Barclays
(2.98)
# 2,601
Out of 4,649 analysts
146
Total ratings
66.1%
Success rate
3.9%
Average return
Main Sectors:
Stocks Rated by James Gordon CFA
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LON: GSK GSK plc | Maintained: Sell | 1,900p | 1,818p | +4.54% | 25 | Aug 12, 2026 | |
| AMS: LKFT Lakefront Biotherapeutics NV | Maintained: Sell | €22.00 | €23.90 | -7.95% | 2 | Aug 11, 2026 | |
| LON: 0MGB Genmab A/S | Reiterated: Buy | kr 2,500 | kr 2,027 | +23.33% | 8 | Aug 10, 2026 | |
| GMAB Genmab | Maintained: Buy | n/a | $31.94 | - | 1 | Aug 7, 2026 | |
| LON: 0QIU Novo Nordisk A/S | Maintained: Hold | kr 300.00 → kr 310.00 | kr 294.70 | +5.19% | 17 | Aug 6, 2026 | |
| SWX: SDZ Sandoz Group AG | Maintained: Buy | CHF 81.00 | CHF 73.00 | +10.96% | 8 | Aug 6, 2026 | |
| LON: 0QW0 argenx SE | Reiterated: Buy | €950.00 → €980.00 | €730.50 | +34.15% | 15 | Jul 29, 2026 | |
| LON: AZN AstraZeneca PLC | Maintained: Buy | 16,500p | 11,460p | +43.98% | 14 | Jul 28, 2026 | |
| ARGX argenx SE | Maintained: Buy | $950 | $851.29 | +11.60% | 1 | Jul 24, 2026 | |
| SWX: GALD Galderma Group AG | Reiterated: Buy | CHF 200.00 → CHF 210.00 | CHF 173.00 | +21.39% | 23 | Jul 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | CHF 120.00 → CHF 125.00 | CHF 122.44 | +2.09% | 9 | Jul 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | kr 530.00 | kr 440.40 | +20.35% | 1 | Jul 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Sell | 1,350p | 1,640p | -17.68% | 3 | Jun 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | CHF 410.00 | CHF 355.10 | +15.46% | 13 | May 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | €85.00 | €75.52 | +12.55% | 6 | Apr 23, 2026 |
GSK plc
Aug 12, 2026
Maintained: Sell
Price Target: 1,900p
Current: 1,818p
Upside: +4.54%
Lakefront Biotherapeutics NV
Aug 11, 2026
Maintained: Sell
Price Target: €22.00
Current: €23.90
Upside: -7.95%
Genmab A/S
Aug 10, 2026
Reiterated: Buy
Price Target: kr 2,500
Current: kr 2,027
Upside: +23.33%
Genmab
Aug 7, 2026
Maintained: Buy
Price Target: n/a
Current: $31.94
Upside: -
Novo Nordisk A/S
Aug 6, 2026
Maintained: Hold
Price Target: kr 300.00 → kr 310.00
Current: kr 294.70
Upside: +5.19%
Sandoz Group AG
Aug 6, 2026
Maintained: Buy
Price Target: CHF 81.00
Current: CHF 73.00
Upside: +10.96%
argenx SE
Jul 29, 2026
Reiterated: Buy
Price Target: €950.00 → €980.00
Current: €730.50
Upside: +34.15%
AstraZeneca PLC
Jul 28, 2026
Maintained: Buy
Price Target: 16,500p
Current: 11,460p
Upside: +43.98%
argenx SE
Jul 24, 2026
Maintained: Buy
Price Target: $950
Current: $851.29
Upside: +11.60%
Galderma Group AG
Jul 24, 2026
Reiterated: Buy
Price Target: CHF 200.00 → CHF 210.00
Current: CHF 173.00
Upside: +21.39%
Jul 22, 2026
Maintained: Hold
Price Target: CHF 120.00 → CHF 125.00
Current: CHF 122.44
Upside: +2.09%
Jul 3, 2026
Maintained: Buy
Price Target: kr 530.00
Current: kr 440.40
Upside: +20.35%
Jun 23, 2026
Maintained: Sell
Price Target: 1,350p
Current: 1,640p
Upside: -17.68%
May 26, 2026
Maintained: Buy
Price Target: CHF 410.00
Current: CHF 355.10
Upside: +15.46%
Apr 23, 2026
Maintained: Hold
Price Target: €85.00
Current: €75.52
Upside: +12.55%